| 1521 |
Autoimmune Hepatitis: Shifts in Gut Microbiota and Metabolic Pathways among Egyptian Patients |
Department of Microbiology and Immunology |
2020 |
| 1522 |
Autoimmune Hepatitis: Shifts in Gut Microbiota and Metabolic Pathways among Egyptian Patients |
Department of Microbiology and Immunology |
2020 |
| 1523 |
Autoimmune Hepatitis: Shifts in Gut Microbiota and Metabolic Pathways among Egyptian Patients |
Department of Gastroenterology and Tropical Medicine |
2020 |
| 1524 |
Autoimmune Hepatitis: Shifts in Gut Microbiota and Metabolic Pathways among Egyptian Patients |
Department of Gastroenterology and Tropical Medicine |
2020 |
| 1525 |
Autoimmune Hepatitis: Shifts in Gut Microbiota and Metabolic Pathways among Egyptian Patients |
Internal Medicine |
2020 |
| 1526 |
Autoimmune Hepatitis: Shifts in Gut Microbiota and Metabolic Pathways among Egyptian Patients |
Internal Medicine |
2020 |
| 1527 |
Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects |
Department of Microbiology and Immunology |
2020 |
| 1528 |
Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes |
Department of Neurology and Psychiatry |
2020 |
| 1529 |
Bioactive Compounds, Pharmacological Actions, and Pharmacokinetics of Wormwood (Artemisia absinthium) |
Department of Microbiology and Immunology |
2020 |
| 1530 |
Bioactive fluorenes. Part III: 2,7-dichloro-9 H-fluorene-based thiazolidinone and azetidinone analogues as anticancer and antimicrobial against multidrug resistant strains agents
|
Department of Microbiology and Immunology |
2020 |
Do you have any questions? 
